Company Filing History:
Years Active: 1998-2000
Title: Innovations of Hans Jonsson
Introduction
Hans Jonsson is a notable inventor based in Uppsala, Sweden. He has made significant contributions to the field of biotechnology, particularly in vaccine development. With a total of two patents to his name, Jonsson's work focuses on innovative methods for delivering vaccines using live Lactobacillus cells.
Latest Patents
One of Jonsson's latest patents is titled "Lactobacilli harboring aggregation gene as a vaccine delivery vehicle." This invention provides live vaccines and methods for preparing them, which are useful in protecting hosts from infections caused by pathogenic microorganisms. The vaccines are derived from live Lactobacillus cells that have been transformed using DNA technology to express heterologous antigens. The genes encoding antigenic determinants pathogenic in the mammalian gastrointestinal tract are inserted into expression cassettes and fused with genes encoding aggregation and mucin binding factors. The inserted genes have been shown to transform L. reuteri cells, enhancing their effectiveness. The vaccine can be ingested orally, either in a pharmaceutical carrier or in milk products.
Another significant patent by Jonsson is "Collagen binding protein as well as its preparation." This invention relates to a new recombinant DNA molecule that comprises a nucleotide sequence from Staphylococcus aureus coding for a protein or polypeptide with collagen binding properties.
Career Highlights
Throughout his career, Hans Jonsson has worked with several prominent companies, including BioGaia Biologics AB and Alfa Laval Corporation AB. His experience in these organizations has contributed to his expertise in biotechnology and vaccine development.
Collaborations
Jonsson has collaborated with notable individuals in his field, including Ivan Casas and Bo Mollstam. These collaborations have likely enriched his research and innovation efforts.
Conclusion
Hans Jonsson's contributions to vaccine technology through his innovative patents demonstrate his commitment to advancing biotechnology. His work continues to have a significant impact on the field, particularly in the development of effective vaccine delivery systems.